%20.png)
SOSTOS
Novel AI-based discoveries of biomarkers and new drug options for significantly life-prolonging outcomes
Our Cutting-Edge Technology
Cancer Treatment Optimization Solutions (CATOS)
Sostos LLC is a provider of cutting-edge artificial intelligence (AI)/big data technologies and health analytics services for precision medicine. CATOS products enable personalized cancer care throughout the patient journey from cancer screening, liquid biopsies, diagnosis, prognosis, treatment selection, to new drug options for patients with failed prior therapy. Our AI technology/software is proven effective in satellite system reliability assurance and precision oncology. Using our AI technology, our developed 7-gene lung cancer assay (CATOS-LU) for prognosis and prediction of therapeutic benefits has been validated in more than 1,600 patients including randomized phase III clinical trials. Using our AI/big data software, we have identified 16 therapeutic compounds as new or repositioning drugs for improving cancer patient survival outcomes. CATOS software can effectively improve cancer theranostics by efficiently analyzing multi-omics profiles of patient single cells, liquid biopsies, biopsies, and bulk tumors. Our technologies have been funded by the NSF, NASA, NIH, CDC, and CPSC.
Sponsors
.jpg)
Academic Publications
Recent publications
Ye Q. and Guo NL, Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks. Biomolecules, 2022, 12, 1782.
Ye Q, Hickey J, Summers K, Falatovich B, Gencheva M, Eubank TD, Ivanov AV, Guo NL. Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival. Int. J. Mol. Sci. 2022, 23, 14978.
Majumder N, Deepak V, Hadique S, Aesoph D, Velayutham M, Ye Q, Mazumder MHH, Lewis SE, Kodali V, Roohollahi A, Guo NL, Hu G, Khramtsov VV, Johnson RJ, Wen S, Kelley EE, Hussain S. Redox imbalance in COVID-19 pathophysiology. Redox biology. 2022; 56, 102465.
Ye Q. and Guo NL, Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. Cancers. 2022 June 25;14(13): 3123.
Ye Q, Falatovich B, Singh S, Ivanov AV, Eubank TD, Guo NL. A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Dec 25;23(1):219.
Ye Q, Singh S, Qian PR, Guo NL. Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer. Cancers. 2021 Aug 26;13(17):4296.
Ye Q, Putila J, Raese R, Dong C, Qian Y, Dowlati A, Guo NL. Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data. Int J Mol Sci. 2021 Jul 17;22(14):7658.
Ye Q, Mohamed R, Dukhlallah D, Gencheva M, Hu G, Pearce MC, Kolluri SK, Marsh CB, Eubank TD, Ivanov AV, Guo NL. Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer. Int J Mol Sci. 2021 Apr 4;22(7):3752.
Guo NL, Bello D, Ye Q, Tagett R, Chanetsa L, Singh D, Poh TY, Setyawati MI, Chotirmall SH, Ng KW, Demokritou P. Pilot deep RNA sequencing of worker blood samples from Singapore printing industry for occupational risk assessment. NanoImpact. 2020; 19, 100248.
Snyder-Talkington BN, Dong C, Singh S, Raese R, Qian Y, Porter DW, Wolfarth MG, Guo NL. Multi-Walled Carbon Nanotube-Induced Gene Expression Biomarkers for Medical and Occupational Surveillance. International journal of molecular sciences. 2019; 20(11), 2635.
Guo NL, Poh TY, Pirela S, Farcas MT, Chotirmall SH, Tham WK, Adav SS, Ye Q, Wei Y, Shen S, Christiani DC, Ng KW, Thomas T, Qian Y, Demokritou P. Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling in Rat Lung, Blood, and Serum for Assessment of Laser Printer-Emitted Nanoparticle Inhalation Exposure-Induced Disease Risks. International journal of molecular sciences. 2019; 20(24), 6348.
Snyder-Talkington BN, Dong C, Castranova V, Qian Y, Guo NL. Differential gene regulation in human small airway epithelial cells grown in monoculture versus coculture with human microvascular endothelial cells following multiwalled carbon nanotube exposure. Toxicology reports. 2019; 6, 482–488.
Guo NL, Dowlati A, Raese R A, et al. A predictive 7-gene assay and prognostic protein biomarkers for non-small cell lung cancer. EBioMedicine, 2018, 32: 102-110.
Our AI technology for satellite system reliability assurance
Ma Y, Guo L, Cukic B, A statistical framework for the prediction of fault-proneness. Advances in Machine Learning Applications in Software Engineering, 237-263, 2007. DOI: 10.4018/978-1-59140-941-1.ch010
Guo L, Mukhopadhyay S, Cukic B. Does Your Result Checker Really Check? Proc. IEEE/IFIP Int Conf Dependable Systems and Networks, Jun-Jul 2004;2004:399-404. DOI: 10.1109/DSN.2004.1311909
Guo L, Cukic B, Singh H. Predicting fault prone modules by the dempster-shafer belief networks. Proc. IEEE International Conference on Automated Software Engineering, Oct;2003:249-252. DOI: 10.1109/ASE.2003.1240314